Paul Ambrose, PharmD

Paul Ambrose, PharmD

Paul G. Ambrose is President of the Institute for Clinical Pharmacodynamics (ICPD), Latham, New York, USA. He is also an Honorary Research Fellow in Infectious Diseases at the University of Oxford, Oxford, UK and Adjunct Associate Research Professor at the University at Buffalo, Buffalo, New York.

Dr. Ambrose’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Knowledge gained though the use of non-clinical (in vitro and animal) PK-PD infection models may be leveraged with human pharmacokinetic data in order to discriminate between potential dosing regimens and thereby increase the probability of positive clinical outcomes while minimizing the potential for drug-related toxicities. ICPD has successfully utilized this approach for support of regulatory decision-making and as support for Clinical and Laboratory Standards Institute susceptibility breakpoint determinations.

Dr. Ambrose is a member of the working group on ‘Skin and Skin Structure Infection-Community-Acquired Pneumonia’ for The Biomarkers Consortium at the National Institutes of Health, Bethesda, Maryland, USA and is a member of the ‘ReAct: Action on Antibiotic Resistance’ Working Group in Uppsala, Sweden.

He is Editor of Antimicrobial Agents Chemotherapy and an Editorial Board Member of the Journal of Infectious Disease Pharmacotherapy. Dr. Ambrose is the author of over 105 peer-reviewed scientific publications and approximately 150 scientific abstracts. Dr. Ambrose has served as an Editor for four textbooks; most notably the 1st and 2nd Editions of Antimicrobial Pharmacodynamics in Theory and Clinical Practice.